Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)

July 1, 2021 07:41 AM EDT

Covid-19 roundup: CureVac pushes ahead for vaccine authorization despite failing to hit 50% efficacy threshold

All mRNA vaccines are not created equal. And Germany-based CureVac found out the hard way on Wednesday as its pivotal trial showed its vaccine is …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Cure­Vac push­es ahead for vac­cine au­tho­riza­tion de­spite fail­ing to hit 50% ef­fi­ca­cy thresh­old